

Yuval Shaked

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1934464/publications.pdf>

Version: 2024-02-01

82
papers

5,526
citations

109264
35
h-index

79644
73
g-index

83
all docs

83
docs citations

83
times ranked

6581
citing authors

#	ARTICLE	IF	CITATIONS
1	T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy. <i>Cancer Research</i> , 2022, 82, 278-291.	0.4	34
2	Photopharmacological modulation of native CRAC channels using azoboronate photoswitches. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2118160119.	3.3	7
3	Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors. <i>JAMA Oncology</i> , 2022, 8, 940.	3.4	2
4	Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade. , 2022, 10, e004582.		16
5	Host response to immune checkpoint inhibitors contributes to tumor aggressiveness. , 2021, 9, e001996.		9
6	Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2239.	1.7	15
7	IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells. , 2021, 9, e002856.		19
8	Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. <i>Cancer Discovery</i> , 2021, 11, 2430-2435.	7.7	44
9	The multifaceted role of mesenchymal stem cells in cancer. <i>Seminars in Cancer Biology</i> , 2020, 60, 225-237.	4.3	112
10	Elucidating the roles of ASPM isoforms reveals a novel prognostic marker for pancreatic cancer. <i>Journal of Pathology</i> , 2020, 250, 123-125.	2.1	10
11	Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. <i>Oncogene</i> , 2020, 39, 187-203.	2.6	34
12	Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth. <i>Cancer Research</i> , 2020, 80, 57-68.	0.4	32
13	Breast Cancer-Derived Microparticles Reduce Cancer Cell Adhesion, an Effect Augmented by Chemotherapy. <i>Cells</i> , 2020, 9, 2269.	1.8	5
14	Lung mechanics modifications facilitating metastasis are mediated in part by breast cancer-derived extracellular vesicles. <i>International Journal of Cancer</i> , 2020, 147, 2924-2933.	2.3	23
15	Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 29.	2.3	26
16	Intratumoral HLA-DR ⁺ /CD33 ⁺ /CD11b ⁺ Myeloid-Derived Suppressor Cells Predict Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1375.	1.3	4
17	The Potential Role of Immune Alteration in the Cancer "COVID19 Equation" A Prospective Longitudinal Study. <i>Cancers</i> , 2020, 12, 2421.	1.7	8
18	IL-31 induces antitumor immunity in breast carcinoma. , 2020, 8, e001010.		9

#	ARTICLE	IF	CITATIONS
19	The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2020, 9, 3912.	1.0	6
20	Early Cardiac Remodeling Promotes Tumor Growth and Metastasis. <i>Circulation</i> , 2020, 142, 670-683.	1.6	63
21	Significance of host heparanase in promoting tumor growth and metastasis. <i>Matrix Biology</i> , 2020, 93, 25-42.	1.5	21
22	Targeting the Interplay Between Cancer Fibroblasts, Mesenchymal Stem Cells, and Cancer Stem Cells in Desmoplastic Cancers. <i>Frontiers in Oncology</i> , 2019, 9, 688.	1.3	85
23	Metronomic Maintenance Therapy for Rhabdomyosarcoma. <i>Trends in Cancer</i> , 2019, 5, 756-759.	3.8	5
24	Copper oxide nanoparticles inhibit pancreatic tumor growth primarily by targeting tumor initiating cells. <i>Scientific Reports</i> , 2019, 9, 12613.	1.6	66
25	ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription. <i>Oncogene</i> , 2019, 38, 3812-3823.	2.6	23
26	Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks. <i>Journal of Clinical Medicine</i> , 2019, 8, 702.	1.0	13
27	Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy. <i>Molecular Cancer Research</i> , 2019, 17, 2331-2340.	1.5	21
28	The pro-tumorigenic host response to cancer therapies. <i>Nature Reviews Cancer</i> , 2019, 19, 667-685.	12.8	135
29	A Unique Crosstalk between Tumor Cells and Hematopoietic Stem Cells Reveals a Myeloid Differentiation Pattern Signature Contributing to Metastasis. <i>Blood</i> , 2019, 134, 2465-2465.	0.6	0
30	Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells. <i>Cancer Research</i> , 2018, 78, 1253-1265.	0.4	81
31	A new screening method for ATP-independent kinase inhibitors identifies repurposed anti-cancer drugs. <i>EBioMedicine</i> , 2018, 37, 21-22.	2.7	0
32	Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach. <i>Oncotarget</i> , 2018, 9, 2574-2590.	0.8	7
33	The potential clinical promise of "multimodality" metronomic chemotherapy revealed by preclinical studies of metastatic disease. <i>Cancer Letters</i> , 2017, 400, 293-304.	3.2	59
34	Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases. <i>Cell Reports</i> , 2017, 19, 774-784.	2.9	82
35	CCR5 Directs the Mobilization of CD11b+Gr1+Ly6Clow Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development. <i>Cell Reports</i> , 2017, 21, 2212-2222.	2.9	83
36	The antiangiogenic role of the pro-inflammatory cytokine interleukin-31. <i>Oncotarget</i> , 2017, 8, 16430-16444.	0.8	24

#	ARTICLE	IF	CITATIONS
37	Next generation metronomic chemotherapy report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. <i>Ecancermedalscience</i> , 2016, 10, 689.	0.6	10
38	Analysis of the Stromal Cellular Components of the Solid Tumor Microenvironment Using Flow Cytometry. <i>Current Protocols in Cell Biology</i> , 2016, 70, 19.18.1-19.18.12.	2.3	20
39	Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy. <i>Journal of Pathology</i> , 2016, 239, 262-273.	2.1	24
40	Therapy-activated stromal cells can dictate tumor fate. <i>Journal of Experimental Medicine</i> , 2016, 213, 2831-2833.	4.2	10
41	Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 611-626.	12.5	103
42	Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy. <i>Cancer Research</i> , 2016, 76, 5983-5993.	0.4	46
43	Heparanase is required for activation and function of macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7808-E7817.	3.3	85
44	Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3. <i>Cell Reports</i> , 2016, 17, 1344-1356.	2.9	88
45	Identification of Dormancy-Associated MicroRNAs for the Design of Osteosarcoma-Targeted Dendritic Polyglycerol Nanopolyplexes. <i>ACS Nano</i> , 2016, 10, 2028-2045.	7.3	64
46	Proteomics of Microparticles with SILAC Quantification (PROMIS-Quan): A Novel Proteomic Method for Plasma Biomarker Quantification*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 1127-1136.	2.5	42
47	Blocking IL1 β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1385-1394.	1.9	60
48	Host effects contributing to cancer therapy resistance. <i>Drug Resistance Updates</i> , 2015, 19, 33-42.	6.5	38
49	Response letter: α -ATF3: A promoter or inhibitor of cardiac maladaptive remodeling. <i>International Journal of Cardiology</i> , 2015, 201, 692.	0.8	4
50	Dequalinium blocks macrophage-induced metastasis following local radiation. <i>Oncotarget</i> , 2015, 6, 27537-27554.	0.8	34
51	Host JDP2 expression in the bone marrow contributes to metastatic spread. <i>Oncotarget</i> , 2015, 6, 37737-37749.	0.8	7
52	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 463.	0.6	26
53	Anti-VEGF-A Affects the Angiogenic Properties of Tumor-Derived Microparticles. <i>PLoS ONE</i> , 2014, 9, e95983.	1.1	13
54	Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: A process regulated by osteopontin. <i>International Journal of Cancer</i> , 2014, 135, 270-281.	2.3	30

#	ARTICLE	IF	CITATIONS
55	Small But Mighty: Microparticles as Mediators of Tumor Progression. <i>Cancer Microenvironment</i> , 2014, 7, 11-21.	3.1	31
56	Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy. <i>Neoplasia</i> , 2014, 16, 501-510.	2.3	60
57	The host immunological response to cancer therapy: An emerging concept in tumor biology. <i>Experimental Cell Research</i> , 2013, 319, 1687-1695.	1.2	21
58	In Vitro Enrichment of Tumor-Initiating Cells from Human Established Cell Lines. <i>Current Protocols in Stem Cell Biology</i> , 2013, 24, Unit 3.7.	3.0	10
59	Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. <i>Drug Discovery Today</i> , 2013, 18, 193-201.	3.2	57
60	Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours. <i>Carcinogenesis</i> , 2013, 34, 2370-2379.	1.3	70
61	Tumor-Initiating Cells of Various Tumor Types Exhibit Differential Angiogenic Properties and React Differently to Antiangiogenic Drugs. <i>Stem Cells</i> , 2012, 30, 1831-1841.	1.4	13
62	G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. <i>Blood</i> , 2011, 118, 3426-3435.	0.6	58
63	Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice. <i>Cancer Research</i> , 2011, 71, 6986-6996.	0.4	102
64	Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF. <i>Cancer Biology and Therapy</i> , 2010, 9, 743-748.	1.5	17
65	The angiogenic profile of colorectal cancer patients following open or laparoscopic colectomy. <i>Cancer Biology and Therapy</i> , 2010, 10, 686-688.	1.5	2
66	Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents. <i>Cancer Research</i> , 2009, 69, 7524-7528.	0.4	78
67	Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. <i>Clinical Cancer Research</i> , 2009, 15, 7652-7657.	3.2	102
68	Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1796, 1-4.	3.3	26
69	Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents. <i>Cancer Cell</i> , 2008, 14, 263-273.	7.7	424
70	Taxanes Induce a Rapid Mobilization of Different Populations of Circulating Endothelial Progenitors by SDF-1 Modulation in Cancer Patients.. <i>Blood</i> , 2008, 112, 1885-1885.	0.6	0
71	Antiangiogenic Strategies on Defense: On the Possibility of Blocking Rebounds by the Tumor Vasculature after Chemotherapy: Figure 1.. <i>Cancer Research</i> , 2007, 67, 7055-7058.	0.4	109
72	Anticancer Therapies Combining Antiangiogenic and Tumor Cell Cytotoxic Effects Reduce the Tumor Stem-Like Cell Fraction in Glioma Xenograft Tumors. <i>Cancer Research</i> , 2007, 67, 3560-3564.	0.4	373

#	ARTICLE	IF	CITATIONS
73	Highly Efficacious Nontoxic Preclinical Treatment for Advanced Metastatic Breast Cancer Using Combination Oral UFT-Cyclophosphamide Metronomic Chemotherapy. <i>Cancer Research</i> , 2006, 66, 3386-3391.	0.4	218
74	Targeted Anti-VEGF Vascular Endothelial Growth Factor Receptor-2 Therapy Leads to Short-term and Long-term Impairment of Vascular Function and Increase in Tumor Hypoxia. <i>Cancer Research</i> , 2006, 66, 3639-3648.	0.4	150
75	Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors. <i>Science</i> , 2006, 313, 1785-1787.	6.0	543
76	The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells. <i>Blood</i> , 2005, 105, 4500-4507.	0.6	34
77	Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. <i>Blood</i> , 2005, 106, 3058-3061.	0.6	252
78	Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis. <i>Cancer Cell</i> , 2005, 7, 101-111.	7.7	332
79	Cellular and Molecular Surrogate Markers to Monitor Targeted and Non-Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose. <i>Current Cancer Drug Targets</i> , 2005, 5, 551-559.	0.8	48
80	Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide Is an Effective Long-term Chemotherapy Treatment Strategy. <i>Cancer Research</i> , 2005, 65, 7045-7051.	0.4	134
81	Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. <i>Cancer Research</i> , 2003, 63, 4342-6.	0.4	375
82	Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0